Danielle Dowell, CSL Seqirus executive director of commercial operations for the Asia Pacific, said the agreement is an important step in helping address unmet need for Australians with high cholesterol.
CSL Seqirus secures Australia-NZ rights to commercialise cholesterol-lowering therapy
March 4, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Eisai and Biogen working on next steps after TGA confirms non-approval of Alzheimer’s therapy
March 4, 2025 - - Latest News -
CSL Seqirus secures Australia-NZ rights to commercialise cholesterol-lowering therapy
March 4, 2025 - - Latest News -
Is personalised gene therapy ready for prime time?
March 4, 2025 - - Latest News -
Astellas welcomes TGA approval of cancer combination as first-line treatment
March 4, 2025 - - Latest News -
Sandoz backs Australian medicinal cannabis company in ten-year agreement
March 3, 2025 - - BioPharma -
Australian startup launches the world's first commercial biological computer
March 3, 2025 - - Australian Biotech -
TGA approves first biological therapy for serious respiratory condition
March 3, 2025 - - Latest News